



Minos Biosciences announces collaboration with Institut Pasteur with the ambition of pioneering new antimicrobial approaches

This partnership is built on the next-generation cell analysis technology developed by Minos Biosciences. The deployment the MinoSuiteTM "Pioneer" platform at the Institut Pasteur marks the kick-off of its early access program.



May 28th, 2025, Paris - MINOS BIOSCIENCES, a deep-tech startup developing next-generation cell analysis technology, announces the official launch of its Early Access Program with the deployment of its MinoSuiteTM Pioneer platform at the Institut Pasteur, within the Dynamics of Host-Pathogen Interactions unit, headed by Dr. Jost ENNINGA.

The strategic collaboration between Minos Biosciences and the teams of Jost ENNINGA and Milena HASAN from the Institut Pasteur, partially funded by the Agence Nationale de la Recherche (ANR) (DynamicHostPathOMICS project - ANR-24-CE19-5557), aims to develop new antimicrobial approaches based on an unprecedented understanding of infection mechanisms.

MinoSuiteTM: a breakthrough in cell analysis

Single-cell analysis has revolutionized biomedical research over the last decade, and represents a market worth over 4 billion Euros by 2024, with very dynamic growth of almost 15% per year. Yet there are still technological impasses limiting the potential of current technologies. MinoSuiteTM, the solution developed by Minos Biosciences, marks a paradigm shift in the analysis of cells and their interactions. For the first time, MinoSuiteTM makes it possible, at cellular resolution, to decipher the molecular mechanisms underlying the behavior of cells in complex biological systems. Thanks to its unique, patented CAGE-tagTM microfluidic technology, MinoSuiteTM combines high-throughput dynamic tracking of cells by imaging and their molecular profiling by sequencing. The result: unrivalled depth and richness of **multidimensional data that can be used to decipher the molecular mechanisms** governing cell behavior and interactions in pathophysiological contexts, enabling the development of new therapeutic or vaccine strategies.

Serving cutting-edge biomedical research with a strong socio-economic impact

Analysing the molecular mechanisms underlying the progression of bacterial, viral or parasitic infections within infected cells is essential to combat infectious diseases in a targeted and effective way. The powerful and unique approach developed by Minos Biosciences makes it possible to meet these challenges, in the context of the persistent threat of global pandemics, the increase in drug-resistant infections and the growing burden of chronic infections.

"Dynamic monitoring of the interactions between infected cells and pathogens, combined with real-time molecular data on the cell's response to successive stages of infection, will enable us to understand the evolution of the response of infected cells and the heterogeneity of these responses from one cell to another. This understanding is key to guiding the development of new antimicrobial strategies and next-generation antibiotics. In view of the preliminary results already obtained with the Minos team, we look forward to deploying Minos technology in our laboratories", says Dr. Jost ENNINGA, Director of the Dynamics of Host-Pathogen Interactions unit at the Institut Pasteur (UMR3691).

A key step in the development of Minos Biosciences

Backed by Elaia Partners, Bpifrance and PSL University, Minos Biosciences has already achieved a number of major technical, scientific and strategic milestones, including the validation of its alpha prototype, and the granting of its core patent in Europe. The launch of its early access program, as part of its collaboration with the Institut Pasteur, marks a new milestone for Minos Biosciences on the road to commercialization of its next-generation cell analysis platform, scheduled for 2027.

"We are both proud and excited to enter into this close partnership with such a renowned institution as the Institut Pasteur, the first deployment site for our early access program. This collaboration provides Minos with a remarkable opportunity to demonstrate the impact of its technology on biomedical research," says Pierre Le Ber, CEO of Minos Biosciences.

"We are particularly pleased with this strategic partnership between Minos Biosciences and the Institut Pasteur, which represents an important step in the validation of Minos' cell analysis technology, the potential of which Elaia Partners had foreseen as early as the seed phase", says Anne-Sophie Carrese, Partner at Elaia Partners.

About Minos Biosciences

Minos Biosciences (www.minos.bio) is a deeptech start-up from the Ecole Supérieure de Physique et Chimie Industrielles de Paris (ESPCI Paris - PSL), housed at the ESPCI's PC'up Scale incubator. Minos Biosciences aims to revolutionize the understanding and treatment of complex diseases such as cancer, infectious and autoimmune diseases. The next-generation cell analysis platform MinoSuite™, developed by Minos Biosciences, opens up new frontiers, from fundamental discovery to drug development and precision medicine.

For further details: <https://youtu.be/uCmeQRuig2A>

About Institut Pasteur

Created by decree in 1887 on the initiative of Louis Pasteur, Institut Pasteur is a world-renowned biomedical research centre. To carry out its mission of fighting disease, in France and worldwide, Institut Pasteur is developing its activities in four areas: research, public health, training and the development of research applications. A recognized world leader in infectious diseases, microbiology and immunology, Institut Pasteur is dedicated to the study of the biology of living organisms. Its work focuses on emerging infectious diseases, antimicrobial resistance, certain cancers, neurodegenerative diseases and brain connectivity pathologies. To reinforce the excellence of its research, Institut Pasteur has and is developing a very high-level technological environment, such as nano-imaging or computational biology and artificial intelligence. Since its creation, 10 researchers working at Institut Pasteur have been awarded the Nobel Prize in Medicine, the most recent in 2008 in recognition of their 1983 discovery of the human immunodeficiency virus (HIV) responsible for AIDS.

Institut Pasteur is a member of Pasteur Network, a global network of more than 30 members on five continents, united by shared Pasteurian values, contributing to the improvement of human health.

Since July 1, 2021, Institut Pasteur has been a partner research organization of Université Paris Cité. <https://www.pasteur.fr/en/press-area>

Press Contacts

Pierre Le Ber - Minos Biosciences - pierre.leber@minosbiosciences.com

Anne Bulet-Parendel, Aurélie Perthuisson - Institut Pasteur Press Office presse@pasteur.fr

Louisa Mesnard - Elaia - lmesnard@elaia.com